Explore this article's sources with AI
Follow PeptideMethods on Google
Tirzepatide response over 12 months
A 249-person tirzepatide cohort reported large 12-month losses, but available-case follow-up and nonrandom dosing limit the conclusion.
Why we wrote this. The headline is easy to overread without the missing-data, dose-selection and prediction limits.
In this article (6 sections)
A retrospective study across 13 obesity practices in Greece found 19.9% mean weight loss at 12 months among 180 adults who had an available measurement while receiving tirzepatide. Half of that measured group lost at least 20% of baseline weight[1]. The result is substantial, but it is an on-treatment, available-case estimate. It does not describe all 249 people who started treatment and cannot establish what individualized dosing caused.
The distinction matters because the study had no placebo or active comparator. Treatment decisions arose in routine care, and every patient paid out of pocket. By 12 months, 170 of 249 starters were still receiving tirzepatide, 64 had confirmed discontinuation and 15 were lost to follow-up[2]. People who remained in care long enough to provide a weight may differ from those without a 12-month measurement.
How the cohort was followed
Angelopoulos and colleagues included consecutive adults who began tirzepatide for weight management between January and July 2025. Eligibility required obesity, or overweight with at least one weight-related condition. Mean starting weight was 113.6 kg and mean body mass index was 39.2 kg/m2. The cohort was 65.5% female, while 13.7% had type 2 diabetes. One third had previously used a GLP-1 receptor agonist[2].
Everyone started at 2.5 mg once weekly as part of clinical care. Later changes were decided by the treating physician with the patient rather than by a study protocol. Response and tolerability shaped those decisions, as did preference and affordability. Lifestyle advice also varied by practice. This makes the dataset useful for describing care, but unsuitable for comparing one dose strategy with another.
Weight loss continued after month six
Among 223 people with paired baseline and six-month weights, mean loss was 14.6%. Among the 180 with paired baseline and 12-month measurements obtained while on treatment, mean loss was 19.9%. In that later group, 88.9% lost at least 10%, 50.0% lost at least 20% and 27.2% lost at least 25%[1]. These percentages use the measured subgroup as the denominator, not all starters.
The paper explored missing outcomes rather than treating the headline as a full-cohort estimate. Under multiple imputation, which assumes missing outcomes can be explained by observed data, estimated mean loss was 19.5%. Scenarios that assigned progressively less loss to people without a 12-month weight produced estimates from 18.6% down to 16.7%. A baseline-observation-carried-forward scenario gave 14.4%. None can reveal the true missing results, so 19.9% should remain an available-case figure.
For 179 participants measured at both follow-ups, 70.4% lost more than another 2% of their month-six weight by month 12. Another 19.6% remained within 2% in either direction, while 10.1% regained more than 2%[2]. Six-month loss did not distinguish those later trajectories. An apparent pause at one visit therefore was not a reliable stopping rule in this cohort.
The predictor result is narrower than it sounds
The investigators asked two different questions about early response. First, did greater loss by month six predict how much more weight a person would lose during the next six months? After adjustment, it did not. The regression coefficient was -0.110 percentage points for each additional percentage point lost by month six, with a 95% confidence interval from -0.255 to 0.035 and P=0.135.
Second, among 139 people who had not yet lost 20% by month six, could early loss identify who would cross that cumulative threshold by month 12? Fifty-two of them did so. Six-month response had moderate discrimination, with an area under the curve of 0.760. Each additional percentage point lost by month six was associated with 1.34 times the adjusted odds of reaching 20% by month 12[2]. That is an association within a selected complete-case subgroup, not an individual forecast.
The paper also derived a 12.5% six-month cutoff in the same cohort used to test it. This is exploratory because no independent group validated the threshold. It should not be used on its own to decide whether someone continues treatment. The model for additional second-half loss explained little of the variation, with an adjusted R2 of 0.067.
Individualized dosing does not prove dose equivalence
Mean dose rose from 7.34 mg at six months to 9.71 mg at 12 months among people with available dose records. Of 160 people recorded at both points, 59.4% moved to a higher dose. The rest stayed on the same dose or moved lower. At month 12, 38.2% of those with dose information remained at 7.5 mg or below, while 31.5% were receiving 12.5 or 15 mg.
People whose dose increased lost more weight during months six through 12 in the unadjusted comparison. After adjustment for clinical factors and six-month response, escalation was not independently associated with additional loss (beta 1.61 percentage points, 95% CI -0.44 to 3.66; P=0.123)[2]. This does not show that higher doses add no benefit. The dose choice was not randomized. A person with slower loss may have been more likely to escalate, while someone satisfied with response may have stayed lower. The observational comparison is confounded by why each dose was chosen.
No reader should treat these dose patterns as a schedule or a reason to change treatment. The study describes physician-guided care within the approved range. The tirzepatide safety overview explains why efficacy, adverse effects and individual contraindications need clinical review.
Persistence and safety need cautious reading
Documented treatment persistence was 68.3% at 12 months. Among the 64 confirmed discontinuations, 21 followed achievement of an individualized goal, 17 were attributed to adverse events and 14 to cost. Twelve followed an inadequate response[1]. Because persistence was observed in a specialist, self-funded setting, it may not transfer to patients with different access or follow-up.
Adverse events came from retrospective clinical records rather than systematic trial surveillance. The authors reported no serious adverse events in the available records, but they acknowledged that mild or transient events could be underreported. Several authors disclosed lecture fees, advisory work or grants involving Pharmaserve-Lilly. Some also disclosed relationships with Novo Nordisk. The study reported no specific grant funding. Those disclosures do not negate the findings, but they belong in the interpretation.
What we do not yet know
The study cannot separate tirzepatide's effect from lifestyle changes, other care or selective retention. Follow-up tests were not standardized, and center-level differences remained after adjustment. Weight maintenance beyond 12 months was not measured. Nor does the cohort establish the comparative effectiveness or cost advantage of any individualized escalation approach.
The most defensible conclusion is narrower than the headline: many measured, continuing patients had large losses, and most with serial weights were still losing after six months. Early response helped classify who reached a cumulative 20% threshold, but it did not predict the amount of later loss. The paper supports continued assessment rather than a dosing formula or a personal promise.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
How much weight did participants lose after 12 months?
Mean loss was 19.9% among 180 participants with an available 12-month measurement obtained while receiving tirzepatide. The baseline cohort had 249 people, so this is not a full-cohort estimate.
Did most people keep losing weight after six months?
Among 179 people measured at both six and 12 months, 70.4% lost more than another 2% of their six-month weight. This selected serial-measurement group does not establish what happened to every starter.
Did early weight loss predict the 12-month result?
It was associated with reaching at least 20% cumulative loss among people below that threshold at month six, but it did not independently predict how much additional weight they lost from months six to 12.
Does this study show that lower tirzepatide doses work as well?
No. Dose choices were not randomized and reflected response, tolerability, preference and cost. The study cannot compare the causal effectiveness of different doses or supply a dosing plan.
Sources
No revisions yet. First published .